|
|
|
|
||
tomorrow Carl June and Sandy MacraeAssessing the safety profile and efficiency of different gene editing technologies and approaches - where are the greatest advances being made? Speaker(s) Carl H. June Dr Carl H. June, Richard W. Vague Professor, Immunotherapy Department - University of Pennsylvania Medical Center Sandy Macrae Dr Sandy Macrae, President & CEO - Sangamo Biosciences In which therapeutic areas and indications are the various gene editing platforms expected to have the greatest impact, both initially and longer term? (Eg. surgical repair, cellular immunotherapy) Curt Herberts Curt Herberts, Senior Vice President & Chief Business Officer - Sangamo BioSciences, Inc http://www.bioleaders-forum.com/cell--gene-therapy-world-2017-agenda and today Therapeutic area clinical update: Monogenic blood disorders Edward R. Conner, MD, Senior Vice President and Chief Medical Officer (CMO) - Sangamo Biosciences |
return to message board, top of board |
Msg # | Subject | Author | Recs | Date Posted |
84752 | Re: tomorrow Carl June and Sandy Macrae | gomasna | 0 | 1/18/2017 10:02:03 AM |
84753 | Re: tomorrow Carl June and Sandy Macrae | pauljd2 | 0 | 1/18/2017 1:35:21 PM |